These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24215160)

  • 1. Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.
    Yu Y; Millar CM
    J Thromb Haemost; 2014 Jan; 12(1):62-70. PubMed ID: 24215160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.
    Visser M; van Oerle R; Ten Cate H; Laux V; Mackman N; Heitmeier S; Spronk HMH
    Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):103-111. PubMed ID: 31766871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
    Waters EK; Hilden I; Sørensen BB; Ezban M; Holm PK
    J Thromb Haemost; 2015 Nov; 13(11):2041-52. PubMed ID: 26340413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
    Enjolras N; Perot E; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Haemophilia; 2015 Jul; 21(4):e317-21. PubMed ID: 25981983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V; Jouppila A; Lassila R
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of seminal factor IX and factor IXa in fertile, nonfertile, and vasectomy subjects: a step closer toward identifying a functional clotting system in human semen.
    Lwaleed BA; Greenfield RS; Hicks J; Birch BR; Cooper AJ
    J Androl; 2005; 26(1):146-52. PubMed ID: 15611579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.
    Kearney KJ; Butler J; Posada OM; Wilson C; Heal S; Ali M; Hardy L; Ahnström J; Gailani D; Foster R; Hethershaw E; Longstaff C; Philippou H
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33397811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor IX mutants with enhanced catalytic activity.
    Hartmann R; Dockal M; Kammlander W; Panholzer E; Nicolaes GA; Fiedler C; Rosing J; Scheiflinger F
    J Thromb Haemost; 2009 Oct; 7(10):1656-62. PubMed ID: 19656280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
    Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
    J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.
    Grover SP; Schmedes CM; Auriemma AC; Butler E; Parrish ML; Miszta A; Cleuren AC; Visser M; Heitmeier S; Posma JJ; Spronk HM; Antoniak S; Wolberg AS; Pawlinski R; Gailani D; Mackman N
    Blood Adv; 2020 Jan; 4(1):207-216. PubMed ID: 31935292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
    Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
    Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation.
    Wan J; Tanratana P; Roest M; Gruber A; Pawlinski R; Wolberg AS; Mackman N; Grover SP
    Blood Adv; 2023 May; 7(9):1915-1925. PubMed ID: 36583671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cell-based model of thrombin generation.
    Roberts HR; Hoffman M; Monroe DM
    Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():32-8. PubMed ID: 16673264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
    Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
    Biochemistry; 2015 Jun; 54(24):3814-21. PubMed ID: 26023895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX.
    Ndonwi M; Broze GJ; Agah S; Schmidt AE; Bajaj SP
    J Biol Chem; 2007 May; 282(21):15632-44. PubMed ID: 17387172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.